24-27 November 2026Crocus Expo, Pavilion 2, Moscow
RU
After a decline last year, the Russian pharmaceutical industry has returned to growth. According to the analytical company RNC Pharma, in January-February 2026, pharmaceutical manufacturers operating in Russia produced more than 630 million packages of finished medicines, which is 6.7% more than in the same period last year. In monetary terms, the volume of production reached 164.9 billion rubles, an increase of 13.8% compared to January-February 2025.
Analysts also note a change in the structure of the market. The share of prescription drugs in the total volume of production exceeded 52% in packages. At the same time, the OTC drug segment continues to decline: over the past three years, their production has consistently declined, and by the end of 2025, the drop was 7.7%.
Among prescription drugs, the most noticeable dynamics was shown by oseltamivir without a brand, which was produced by seven Russian companies in the reporting period. The volume of production of this item has tripled. Among prescription brands, the growth leader was Prevenar, produced at the Petrovax production site in Podolsk: its production volumes also tripled.
In the segment of OTC drugs, the highest dynamics at the beginning of 2026 was demonstrated by Miramistin, manufactured by Infamed. Over the year, the volume of production of this drug has increased 43 times.
An additional indicator of the development of the industry was the results of the analysis of the public procurement market. The Cursor analytical platform has presented a rating of full-cycle manufacturers at the end of 2025. According to the report, by the beginning of 2026, the Ministry of Industry and Trade of Russia confirmed the full production cycle for 169 international nonproprietary names. The leader of the rating in terms of sales was Biocad with a result of 48.8 billion rubles, which is 42% of the full-cycle drugs market.
The growth in production volumes and the development of the full-cycle segment confirm the continued strengthening of Russian pharmaceutical capacities, as well as changes in the structure of supply in the domestic market.
*Source: GxP News.
